Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Mecamylamine hydrochloride (Inversine) Clear all

Conditions: Cognition in Schizophrenia
Interventions: Mecamylamine, Varenicline, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcoholism
Interventions: mecamylamine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: TC-5214, Duloxetine, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 22 more

Conditions: HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions: Scopolamine Injectable Product, Mecamylamine Pill; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions: Cholinergic antagonist; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Nashville, Tennessee • Burlington, Vermont

Conditions: Subjective Cognitive Decline
Interventions: Mecamylamine Challenge, Placebo Comparator Challenge; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autistic Disorder, Pervasive Developmental Disorder
Interventions: mecamylamine, placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 4 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Aging
Interventions: Nicotine patch, oral mecamylamine, placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Major Depressive Disorder, MDD, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 93
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more

Conditions: Spinal Cord Injuries
Interventions: Mecamylamine Oral Tablet; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Alcohol Dependence, Depression
Interventions: Mecamylamine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Diabetic Macular Edema
Interventions: mecamylamine; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Oakland, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
Interventions: Placebo, Nicotine, Mecamylamine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 79
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more

Conditions: Nicotine Dependence
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Catonsville, Maryland

Conditions: Smoking
Interventions: Mecamylamine, Nicotine Patch, Cigarette brand switching; Drug · Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Subjects
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Subjective Cognitive Decline
Interventions: Mecamylamine Challenge, Placebo Comparator Challenge; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depressive Disorder
Interventions: Mecamylamine hydrochloride (Inversine); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking
Interventions: Bupropion, Mecamylamine, Nicotine Patch; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 20 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Mental Ability Challenge Study in Adults With and Without HIV

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Cholinergic Health After Menopause (CHAMP)

Cholinergic Mechanisms of Attention in Aging

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

The Nicotinic Cholinergic System and Cognitive Aging

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Mecamylamine for Autonomic Dysreflexia Prophylaxis

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Nicotinic Modulation of the Default Network

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Nicotinic Modulation of the Default Network of Resting Brain Function

Treatment to Quit Smoking

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

Attentional Mechanisms in SCD

Nicotinic Receptor Augmentation of SSRI Antidepressants

Treatment of Orthostatic Intolerance

Combinations of Pharmacologic Smoking Cessation Treatments